{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:43:51Z","timestamp":1784004231439,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Beh\u00e7et\u2019s Disease (BD) is an autoimmune disease mostly presenting with recurrent oral and genital aphthosis, and uveitis. Patients are rarely refractory to immunosuppressive treatments. Autologous hematopoietic stem cell transplantation (aHSCT) is a standard of care in other autoimmune diseases. Some patients with BD have been treated with aHSCT based on compassionate use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Evaluate the outcome of aHSCT in adult patients with BD treated in member centers of the European Society for Blood and Marrow Transplantation (EBMT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults who received aHSCT primarily for BD were identified retrospectively in the EBMT registry and\/or in published literature. Data were extracted from either medical records of the patient or from publications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight out of 9 cases reported to the registry and extracted data of 2 further patients from literature were analyzed. Four were female, median age at onset of BD was 24y (range 9-50). Median age at aHSCT was 32y (27-51). Patients had received median 4 (2-11) previous lines of therapy (89% corticosteroids, 50% methotrexate, anti-TNF\u03b1 therapy or cyclophosphamide). All patients had active disease before mobilization. Conditioning regimen was heterogeneous. Median follow-up was 48 months (range 6-240). No treatment-related mortality was reported. This procedure induced complete remission (CR) in 80%, partial remission in 10% and lack of response in 10% of the patients. Relapse rate was 30% (2 relapses in patients in CR and 1 relapse in the patient in PR) with panuveitis (n=1), aphthosis (n=2) and arthralgia (n=1). Six patients were in CR. No late complications were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>aHSCT has an acceptable safety profile and represents a feasible and relatively effective procedure in severe and conventional treatment-resistant cases of BD and has the potential to stabilize BD in patients with life-threatening involvements.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.638709","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T05:48:56Z","timestamp":1620280136000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Autologous Hematopoietic Stem Cell Transplantation for Beh\u00e7et\u2019s Disease: A Retrospective Survey of Patients Treated in Europe, on Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation"],"prefix":"10.3389","volume":"12","author":[{"given":"Mathieu","family":"Puyade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong Jer","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Badoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gualandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Maximova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/1744666X.2016.1205486","article-title":"Behcet\u2019s disease: epidemiology, clinical manifestations, and diagnosis","volume":"13","author":"Davatchi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.2.115","article-title":"Validation of the International Study Group criteria for Beh\u00e7et\u2019s disease","volume":"33","author":"O\u2019Neill","year":"1994","journal-title":"Br J Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/607921","article-title":"Diagnosis\/Classification Criteria for Behcet\u2019s Disease","volume":"2012","author":"Davatchi","year":"2012","journal-title":"Pathol Res Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: Multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmunity"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.251","article-title":"SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking","volume":"50","author":"Alexander","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2017.06.019","article-title":"Indications et suivi des autogreffes de cellules souches h\u00e9matopo\u00ef\u00e9tiques dans les maladies auto-immunes et auto-inflammatoires\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"104","author":"Pugnet","year":"2017","journal-title":"Bull du Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez300","article-title":"Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review","volume":"59","author":"Puyade","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017010041","article-title":"Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","article-title":"Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)","volume":"55","author":"Sharrack","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.16700","article-title":"Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial","volume":"314","author":"Hawkey","year":"2015","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.056630","article-title":"Haematopoietic stem cell transplantation for vasculitis including Behcet\u2019s disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature","volume":"66","author":"Daikeler","year":"2006","journal-title":"Ann Rheumatic Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802474447","article-title":"Treatment of Beh\u00e7et\u2019s syndrome and plasmacytoma in a patient with peripheral blood stem cell transplantation","volume":"49","author":"Chauhan","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket479","article-title":"Bone marrow transplantation for Behcet\u2019s disease: a case report and systematic review of the literature","volume":"53","author":"Soysal","year":"2014","journal-title":"Rheumatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101043440121","article-title":"Autologous Hematopoietic Stem-Cell Transplantation for Beh\u00e7et\u2019s Disease with Pulmonary Involvement","volume":"344","author":"Hensel","year":"2001","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/039463200702000110","article-title":"Prolonged Remission of Neuro-Behcet Disease following Autologous Transplantation","volume":"20","author":"De Cata","year":"2007","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3617","article-title":"Autologous hematopoietic stem cell transplantation for severe\/refractory intestinal Behcet disease","volume":"103","author":"Rossi","year":"2004","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070227","article-title":"Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis","volume":"67","author":"Statkute","year":"2008","journal-title":"Ann Rheumatic Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/08916930802197495","article-title":"Hematopoietic stem cell transplantation (HSCT) for primary systemic vasculitis and related diseases","volume":"41","author":"Fiehn","year":"2008","journal-title":"Autoimmunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx054","article-title":"Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn\u2019s Disease: Efficacy in a Single-Centre Cohort","volume":"11","author":"L\u00f3pez-Garc\u00eda","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B25","article-title":"Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR","volume":"31","author":"Snowden","year":"2004","journal-title":"J Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaut.2018.06.002","article-title":"Hematopoietic stem cell therapy for autoimmune diseases \u2013 Clinical experience and mechanisms","volume":"92","author":"Alexander","year":"2018","journal-title":"J Autoimmunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1297232","article-title":"Progress and prospects for the use and the understanding of the mode of action of autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis","volume":"13","author":"Collins","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2016.03.004","article-title":"Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases","volume":"64","author":"Arruda","year":"2016","journal-title":"Curr Res Trans Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0162-0","article-title":"Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis","volume":"53","author":"Arruda","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0388-5","article-title":"Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients","volume":"10","author":"Farge","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.21036","article-title":"Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis","volume":"52","author":"Farge","year":"2005","journal-title":"Arthritis Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168286","article-title":"Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system","volume":"113","author":"Alexander","year":"2009","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017011072","article-title":"Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients","volume":"2","author":"Arruda","year":"2018","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-4-329","article-title":"Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist","volume":"18","author":"Snowden","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.035410","article-title":"Autologous haematopoietic stem cell transplantation for Behcet\u2019s Disease with pulmonary involvement : analysis after 5 years of follow-up","volume":"65","author":"Maurer","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.638709\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T05:49:00Z","timestamp":1620280140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.638709\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2021.638709"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.638709","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"article-number":"638709"}}